A novel micelleplex for tumour-targeted delivery of CRISPR-Cas9 against KRAS-mutated lung cancer
Nanoscale · 2025
DOI: 10.1039/d4nr03471f ↗At a glance
Journal article in Nanoscale, 2025. Written by Siyu Chen and 3 co-authors. Institution: Ludwig-Maximilians-University, Department of Pharmacy, Pharmaceutical Technology and Biopharmaceutics, Butenandtstraße 5-13, Munich, 81377, Germany. …. Major MEDLINE topics: Lung Neoplasms, Micelles, Proto-Oncogene Proteins p21(ras), CRISPR-Cas Systems. Cited 8 times so far (Crossref); 72 references. The full text is freely available (open access, CC BY 3.0). Funded by: China Scholarship Council, Alexander von Humboldt-Stiftung, H2020 European Research Council.
Abstract (original language)
CRISPR-Cas9 has emerged as a highly effective and customizable genome editing tool, holding significant promise for the treatment of KRAS mutations in lung cancer.
Subjects
MeSH terms (MEDLINE)
Substances
Authors and institutions
- Ludwig-Maximilians-University, Department of Pharmacy, Pharmaceutical Technology and Biopharmaceutics, Butenandtstraße 5-13, Munich, 81377, Germany. siyu.chen@cup.uni-muenchen.de.
Funding
- China Scholarship Council
- Alexander von Humboldt-Stiftung
- H2020 European Research Council
Cite
APA
Chen, S., Triki, M., Pinto Carneiro, S., & Merkel, O. M. (2025). A novel micelleplex for tumour-targeted delivery of CRISPR-Cas9 against KRAS-mutated lung cancer. Nanoscale. https://doi.org/10.1039/d4nr03471f
Vancouver
Chen S, Triki M, Pinto Carneiro S, Merkel OM. A novel micelleplex for tumour-targeted delivery of CRISPR-Cas9 against KRAS-mutated lung cancer. Nanoscale. 2025. doi:10.1039/d4nr03471f
BibTeX
@article{Chen2025,
author = {Chen, Siyu and Triki, Mariem and Pinto Carneiro, Simone and Merkel, Olivia Monika},
title = {A novel micelleplex for tumour-targeted delivery of CRISPR-Cas9 against KRAS-mutated lung cancer},
journal = {Nanoscale},
year = {2025},
doi = {10.1039/d4nr03471f}
}
EUVIMED